| DOI | Trouver le DOI : https://doi.org/10.1016/0014-5793(86)80877-8 |
|---|
| Auteur | Rechercher : Ingold, K. U.1; Rechercher : Burton, G.W.1; Rechercher : Foster, D.O.1; Rechercher : Zuker, M.1; Rechercher : Hughes, L.1; Rechercher : Lacelle, S.1; Rechercher : Lusztyk, E.1; Rechercher : Slaby, M.1 |
|---|
| Affiliation | - Conseil national de recherches du Canada
|
|---|
| Format | Texte, Article |
|---|
| Sujet | 3,4 dihydro 5 hydroxy 2,4,6,7 tetramethyl 2 (4,8,12 trimethyltridecyl)benzofuran acetate; alpha tocopherol; pyruvate kinase; unclassified drug; animal experiment; biological model; blood and hemopoietic system; drug comparison; drug screening; drug synthesis; muscle; muscle disease; oral drug administration; rat; Diet; Kinetics; Male; Muscles; Pyruvate Kinase; Rats; Rats, Inbred Strains; Stereoisomerism; Vitamin E; Vitamin E Deficiency; Animalia |
|---|
| Résumé | Vitamin E owes its biological effects to its antioxidant activity. Kinetic and mechanistic studies on phenolic antioxidants in vitro have led us to design and synthesize all-rac-2,4,6,7-tetramethyl-2-(4',8',12'-trimethyltridecyl)-5-hydroxy-3,4-dihydrobenzofuran, 3. In the rat curative myopathy bioassay the acetate of this compound has 1.5-1.9 times the bioactivity of all-rac-α-tocopherol acetate. This represents the first time that a rationally designed synthetic 'vitamin' has been found to have more activity in vivo than the corresponding natural vitamin. © 1986. |
|---|
| Date de publication | 1986 |
|---|
| Dans | |
|---|
| Langue | anglais |
|---|
| Publications évaluées par des pairs | Oui |
|---|
| Numéro NPARC | 21276632 |
|---|
| Exporter la notice | Exporter en format RIS |
|---|
| Signaler une correction | Signaler une correction (s'ouvre dans un nouvel onglet) |
|---|
| Identificateur de l’enregistrement | 4bd2bb40-bfa9-495b-addd-74508add7b3d |
|---|
| Enregistrement créé | 2015-10-13 |
|---|
| Enregistrement modifié | 2020-03-17 |
|---|
